Curatis identifies potential drug candidates for a repurposing development approach in indications with high unmet medical needs via its extensive network within the scientific and medical community, as well as within the biotech/pharmaceutical industry. Curatis invests a significant portion of its revenues and resources in its development activities.
The current pipeline is a balance of preclinical and clinical compounds with clinically validated targets.
|Molecule||Pre-clinical||Phase I||Phase II||Phase III||Market|
|C-H-01||prevention of frequent episodic tension type headache|
|C-M-01||prevention of severe migraine with aura|
*Amyotrophic lateral sclerosis